Now showing items 1-2 of 2

    • Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort 

      Kirk, Peter S.; Lotan, Yair; Zargar, Homayoun; Zargar, Kamran; Fairey, Adrian S; Dinney, Colin P; Mir, Maria C; Krabbe, Laura-Maria; Cookson, Michael S; Jacobson, Niels-Erik; Montgomery, Jeffrey S; Vasdev, Nikhil; Yu, Evan Y; Xylinas, Evanguelos; Kassouf, Wassim; Dall'Era, Marc A; Sridhar, Srikala S.; McGrath, Jonathan S; Aning, Jonathan; Shariat, Shahrokh F; Thorpe, Andrew C.; Morgan, Todd M; Holzbeierlein, Jeff M; Bivalacqua, Trinity J; North, Scott; Barocas, Daniel A; Grivas, Petros; Garcia, Jorge A; Stephenson, Andrew J; Shah, Jay B; Daneshmand, Siamek; Spiess, Philippe E; van Rhijn, Bas WG; Black, Peter C.; Wright, Jonathan L. (2023-05-01)
      Purpose: While the presence of residual disease at the time of radical cystectomy for bladder cancer is an established prognostic indicator, controversy remains regarding the importance of maximal transurethral resection ...
    • Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer 

      Einerhand, Sarah MH; Black, Anna J; Zargar, Homayoun; Fairey, Adrian S.; Dinney, Colin P; Mir, Maria C; Krabbe, Laura-Maria; Cookson, Michael S.; Jacobson, Niels-Erik; Montgomery, Jeffrey S; Vasdev, Nikhil; Yu, Evan Y; Xylinas, Evanguelos; Kassouf, Wassim; Dall’Era, Marc A.; Sridhar, Srikala S.; McGrath, Jonathan S; Aning, Jonathan; Shariat, Shahrokh F; Wright, Jonathan L.; Thorpe, Andrew C.; Morgan, Todd M; Holzbeierlein, Jeff M.; Bivalacqua, Trinity J; North, Scott; Barocas, Daniel A.; Lotan, Yair; Grivas, Petros; Garcia, Jorge A; Stephenson, Andrew J; Shah, Jay B; Daneshmand, Simak; Zargar-Shoshtari, Kamran; Spiess, P. E.; van Rhijn, Bas W; Black, Peter C.; Mertens, L. S. (2022-09-28)
      PurposeCisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin-ineligible. The aim of this study ...